Nathaniel Herzfeld

Array ( [id] => 16893194 [patent_doc_number] => 11034727 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-15 [patent_title] => Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy [patent_app_type] => utility [patent_app_number] => 15/778626 [patent_app_country] => US [patent_app_date] => 2016-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 31 [patent_no_of_words] => 26510 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15778626 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13049293 [patent_doc_number] => 10046023 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-14 [patent_title] => FC receptor (FcRn) binding peptides and uses thereof [patent_app_type] => utility [patent_app_number] => 15/354375 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 29 [patent_no_of_words] => 44899 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15354375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13589929 [patent_doc_number] => 20180346513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => METHOD FOR OBTAINING TUMOR PEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/775592 [patent_app_country] => US [patent_app_date] => 2016-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17651 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15775592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13490195 [patent_doc_number] => 20180296640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => Peptides and Method for Treatment of Cardiac Arrest [patent_app_type] => utility [patent_app_number] => 15/769132 [patent_app_country] => US [patent_app_date] => 2016-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9069 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15769132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11625909 [patent_doc_number] => 20170136099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-18 [patent_title] => 'SURFACTANT PROTEIN D FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH LUNG INJURY' [patent_app_type] => utility [patent_app_number] => 15/341383 [patent_app_country] => US [patent_app_date] => 2016-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8091 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15341383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17513695 [patent_doc_number] => 11292825 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-05 [patent_title] => Protein conjugates [patent_app_type] => utility [patent_app_number] => 15/763857 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 30546 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15763857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14294449 [patent_doc_number] => 10287341 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-14 [patent_title] => Single domain binding molecule [patent_app_type] => utility [patent_app_number] => 15/273197 [patent_app_country] => US [patent_app_date] => 2016-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 15 [patent_no_of_words] => 12074 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15273197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16640290 [patent_doc_number] => 10918104 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-16 [patent_title] => Elicitor peptides having disrupted hypersensitive response box and use thereof [patent_app_type] => utility [patent_app_number] => 15/244862 [patent_app_country] => US [patent_app_date] => 2016-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28294 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15244862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16588661 [patent_doc_number] => 10897900 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Hypersensitive response elicitor peptides and use thereof [patent_app_type] => utility [patent_app_number] => 15/244707 [patent_app_country] => US [patent_app_date] => 2016-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 26 [patent_no_of_words] => 32573 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15244707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16490532 [patent_doc_number] => 10856547 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-08 [patent_title] => Hypersensitive response elicitor peptides and use thereof [patent_app_type] => utility [patent_app_number] => 15/244748 [patent_app_country] => US [patent_app_date] => 2016-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 26 [patent_no_of_words] => 32457 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15244748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15337645 [patent_doc_number] => 10524473 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-07 [patent_title] => Elicitor peptides having disrupted hypersensitive response box and use thereof [patent_app_type] => utility [patent_app_number] => 15/244919 [patent_app_country] => US [patent_app_date] => 2016-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28342 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15244919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13339691 [patent_doc_number] => 20180221385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => A PHARMACEUTICAL PREPARATION FOR IMPROVING ABSORPTION AND POSTPRANDIAL HYPOGLYCEMIC ACTION OF INSULIN [patent_app_type] => utility [patent_app_number] => 15/747532 [patent_app_country] => US [patent_app_date] => 2016-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15747532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11663574 [patent_doc_number] => 20170152293 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-01 [patent_title] => 'RECOMBINANT CYTOTOXIN AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/219496 [patent_app_country] => US [patent_app_date] => 2016-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 5197 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15219496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14326563 [patent_doc_number] => 10294285 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-21 [patent_title] => Modification and compositions of human secretoglobin proteins [patent_app_type] => utility [patent_app_number] => 15/212277 [patent_app_country] => US [patent_app_date] => 2016-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 10625 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15212277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13339789 [patent_doc_number] => 20180221434 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => Multi-Peptide Composition [patent_app_type] => utility [patent_app_number] => 15/580791 [patent_app_country] => US [patent_app_date] => 2016-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6268 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15580791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11100882 [patent_doc_number] => 20160297853 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-13 [patent_title] => 'ELICITOR PEPTIDES HAVING DISRUPTED HYPERSENSITIVE RESPONSE BOX AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/179453 [patent_app_country] => US [patent_app_date] => 2016-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30670 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15179453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11067661 [patent_doc_number] => 20160264625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'ADVANTAGEOUS MU-OPIATE RECEPTOR PEPTIDE COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 15/168158 [patent_app_country] => US [patent_app_date] => 2016-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2132 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15168158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11541756 [patent_doc_number] => 20170095581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-06 [patent_title] => 'BISPECIFIC PEPTIDE CONJUGATE AND RADIOACTIVE BISPECIFIC PEPTIDE IMAGING AGENT' [patent_app_type] => utility [patent_app_number] => 15/157905 [patent_app_country] => US [patent_app_date] => 2016-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 2694 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15157905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17406097 [patent_doc_number] => 11246958 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Haemostatic compositions [patent_app_type] => utility [patent_app_number] => 15/572915 [patent_app_country] => US [patent_app_date] => 2016-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 17523 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15572915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11047550 [patent_doc_number] => 20160244508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-25 [patent_title] => 'USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS' [patent_app_type] => utility [patent_app_number] => 15/152468 [patent_app_country] => US [patent_app_date] => 2016-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 24759 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15152468 [rel_patent_id] =>[rel_patent_doc_number] =>)